CNS Delivery of Nucleic Acid Therapeutics: Beyond the Blood-Brain Barrier and Towards Specific Cellular Targeting

Overview

Journal Pharm Res

Specialties Pharmacology
Pharmacy

Date 2022 Nov 15

PMID 36380168

Authors

Anisha DSouza

Saeideh Nozohouri

Benjamin S Bleier

Mansoor M Amiji

Affiliations

Soon will be listed here.

Abstract

Nucleic acid-based therapeutic molecules including small interfering RNA (siRNA), microRNA(miRNA), antisense oligonucleotides (ASOs), messenger RNA (mRNA), and DNA-based gene therapy have tremendous potential for treating diseases in the central nervous system (CNS). However, achieving clinically meaningful delivery to the brain and particularly to target cells and sub-cellular compartments is typically very challenging. Mediating cell-specific delivery in the CNS would be a crucial advance that mitigates off-target effects and toxicities. In this review, we describe these challenges and provide contemporary evidence of advances in cellular and sub-cellular delivery using a variety of delivery mechanisms and alternative routes of administration, including the nose-to-brain approach. Strategies to achieve subcellular localization, endosomal escape, cytosolic bioavailability, and nuclear transfer are also discussed. Ultimately, there are still many challenges to translating these experimental strategies into effective and clinically viable approaches for treating patients.

Citing Articles

Targeted lipid nanoparticles distributed in hydrogel treat osteoarthritis by modulating cholesterol metabolism and promoting endogenous cartilage regeneration.

Zhao Z, Wang P, Li Z, Wei X, Li S, Lu X J Nanobiotechnology. 2024; 22(1):786.

PMID: 39707367 PMC: 11662830. DOI: 10.1186/s12951-024-02965-9.

RNA structure in alternative splicing regulation: from mechanism to therapy.

Bao N, Wang Z, Fu J, Dong H, Jin Y Acta Biochim Biophys Sin (Shanghai). 2024; 57(1):3-21.

PMID: 39034824 PMC: 11802352. DOI: 10.3724/abbs.2024119.

Functionalized nanoparticles to deliver nucleic acids to the brain for the treatment of Alzheimer's disease.

Muolokwu C, Chaulagain B, Gothwal A, Mahanta A, Tagoe B, Lamsal B Front Pharmacol. 2024; 15:1405423.

PMID: 38855744 PMC: 11157074. DOI: 10.3389/fphar.2024.1405423.

Brain-Targeted Liposomes Loaded with Monoclonal Antibodies Reduce Alpha-Synuclein Aggregation and Improve Behavioral Symptoms in Parkinson's Disease.

Sela M, Poley M, Mora-Raimundo P, Kagan S, Avital A, Kaduri M Adv Mater. 2023; 35(51):e2304654.

PMID: 37753928 PMC: 7615408. DOI: 10.1002/adma.202304654.

Nucleic acid-based therapeutics for the treatment of central nervous system disorders.

McCartan R, Khorkova O, Volmar C, Wahlestedt C Front Genet. 2023; 14:1250276.

PMID: 37662844 PMC: 10468602. DOI: 10.3389/fgene.2023.1250276.

References

Simonato M, Bennett J, Boulis N, Castro M, Fink D, Goins W . Progress in gene therapy for neurological disorders. Nat Rev Neurol. 2013; 9(5):277-91. PMC: 3908892. DOI: 10.1038/nrneurol.2013.56. View

Giacobbo B, Doorduin J, Klein H, Dierckx R, Bromberg E, de Vries E . Brain-Derived Neurotrophic Factor in Brain Disorders: Focus on Neuroinflammation. Mol Neurobiol. 2018; 56(5):3295-3312. PMC: 6476855. DOI: 10.1007/s12035-018-1283-6. View

Nagabhushan Kalburgi S, Khan N, Gray S . Recent gene therapy advancements for neurological diseases. Discov Med. 2013; 15(81):111-9. PMC: 5554939. View

Piguet F, Alves S, Cartier N . Clinical Gene Therapy for Neurodegenerative Diseases: Past, Present, and Future. Hum Gene Ther. 2017; 28(11):988-1003. DOI: 10.1089/hum.2017.160. View

Cicalese M, Aiuti A . New perspectives in gene therapy for inherited disorders. Pediatr Allergy Immunol. 2020; 31 Suppl 24:5-7. DOI: 10.1111/pai.13149. View

Sung Y, Kim S . Recent advances in the development of gene delivery systems. Biomater Res. 2019; 23:8. PMC: 6417261. DOI: 10.1186/s40824-019-0156-z. View

Bulaklak K, Gersbach C . The once and future gene therapy. Nat Commun. 2020; 11(1):5820. PMC: 7670458. DOI: 10.1038/s41467-020-19505-2. View

Pan X, Veroniaina H, Su N, Sha K, Jiang F, Wu Z . Applications and developments of gene therapy drug delivery systems for genetic diseases. Asian J Pharm Sci. 2022; 16(6):687-703. PMC: 8737406. DOI: 10.1016/j.ajps.2021.05.003. View

Alagoz M, Kherad N . Advance genome editing technologies in the treatment of human diseases: CRISPR therapy (Review). Int J Mol Med. 2020; 46(2):521-534. PMC: 7307811. DOI: 10.3892/ijmm.2020.4609. View

10.

Khalil A . The genome editing revolution: review. J Genet Eng Biotechnol. 2020; 18(1):68. PMC: 7596157. DOI: 10.1186/s43141-020-00078-y. View

11.

Pezzoli D, Chiesa R, De Nardo L, Candiani G . We still have a long way to go to effectively deliver genes!. J Appl Biomater Funct Mater. 2012; 10(2):82-91. DOI: 10.5301/JABFM.2012.9707. View

12.

Klug B, Celis P, Carr M, Reinhardt J . Regulatory structures for gene therapy medicinal products in the European Union. Methods Enzymol. 2012; 507:337-54. DOI: 10.1016/B978-0-12-386509-0.00017-X. View

13.

Paunovska K, Loughrey D, Dahlman J . Drug delivery systems for RNA therapeutics. Nat Rev Genet. 2022; 23(5):265-280. PMC: 8724758. DOI: 10.1038/s41576-021-00439-4. View

14.

Deverman B, Ravina B, Bankiewicz K, Paul S, Sah D . Gene therapy for neurological disorders: progress and prospects. Nat Rev Drug Discov. 2018; 17(9):641-659. DOI: 10.1038/nrd.2018.110. View

15.

Bobbin M, Rossi J . RNA Interference (RNAi)-Based Therapeutics: Delivering on the Promise?. Annu Rev Pharmacol Toxicol. 2016; 56:103-22. DOI: 10.1146/annurev-pharmtox-010715-103633. View

16.

Lorenzer C, Dirin M, Winkler A, Baumann V, Winkler J . Going beyond the liver: progress and challenges of targeted delivery of siRNA therapeutics. J Control Release. 2015; 203:1-15. DOI: 10.1016/j.jconrel.2015.02.003. View

17.

Havens M, Hastings M . Splice-switching antisense oligonucleotides as therapeutic drugs. Nucleic Acids Res. 2016; 44(14):6549-63. PMC: 5001604. DOI: 10.1093/nar/gkw533. View

18.

Sridharan K, Gogtay N . Therapeutic nucleic acids: current clinical status. Br J Clin Pharmacol. 2016; 82(3):659-72. PMC: 5338117. DOI: 10.1111/bcp.12987. View

19.

Geary R, Norris D, Yu R, Bennett C . Pharmacokinetics, biodistribution and cell uptake of antisense oligonucleotides. Adv Drug Deliv Rev. 2015; 87:46-51. DOI: 10.1016/j.addr.2015.01.008. View

20.

Hock J, Meister G . The Argonaute protein family. Genome Biol. 2008; 9(2):210. PMC: 2374724. DOI: 10.1186/gb-2008-9-2-210. View